These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Role of prohepcidin, inflammatory markers and iron status in resistance to rhEPO therapy in hemodialysis patients. Costa E, Pereira BJ, Rocha-Pereira P, Rocha S, Reis F, Castro E, Teixeira F, Miranda V, do Sameiro Faria M, Loureiro A, Quintanilha A, Belo L, Santos-Silva A. Am J Nephrol; 2008; 28(4):677-83. PubMed ID: 18354252 [Abstract] [Full Text] [Related]
7. Reproducibility of and correspondence among different hepcidin forms in blood and urine and their relationships to iron status in healthy, male Guatemalan volunteers observed over 9 weeks. Schuemann K, Solomons NW, Laarakkers CM, Romero-Abal ME, Kroll S, Weiss G, Swinkels DW. Ann Nutr Metab; 2011; 58(2):158-66. PubMed ID: 21654163 [Abstract] [Full Text] [Related]
8. [Serum prohepcidin and other iron metabolism parameters in healthy adults]. Zekanowska E, Boinska J, Kwapisz J, Kedziora-Kornatowska K, Porzych K, Ratajczak M. Przegl Lek; 2011; 68(2):82-6. PubMed ID: 21751515 [Abstract] [Full Text] [Related]
9. How does short-term low-dose simvastatin influence serum prohepcidin levels in patients with end-stage renal disease? A pilot study. Li XY, Chang JP, Su ZW, Li JH, Peng BS, Zhu SL, Cai AJ, Zhang J, Jiang Y. Ther Apher Dial; 2010 Jun; 14(3):308-14. PubMed ID: 20609184 [Abstract] [Full Text] [Related]
11. Serum hepcidin but not prohepcidin may be an effective marker for anemia of inflammation (AI). Sasu BJ, Li H, Rose MJ, Arvedson TL, Doellgast G, Molineux G. Blood Cells Mol Dis; 2010 Oct 15; 45(3):238-45. PubMed ID: 20800515 [Abstract] [Full Text] [Related]